Department of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation Center, The Calmette Affiliated Hospital of Kunming Medical University, The First People's Hospital of Kunming, Kunming, China.
Clin Transl Oncol. 2023 Jul;25(7):2099-2115. doi: 10.1007/s12094-023-03084-x. Epub 2023 Jan 28.
Hepatocellular carcinoma (HCC) is a highly vascularized tumor, and angiogenesis plays an important role in its progression. However, the role of angiogenesis in cell infiltration in the tumor microenvironment (TME) remains unclear.
We evaluated the associations of 35 angiogenesis-related genes (ARGs) with the clinicopathological features of 816 HCC patients. In addition, we assessed the associations between the ARGs and TME cell infiltration. A nomogram was constructed to determine the prognostic value of ARGs for HCC. The ARG score was used to distinguish angiogenic subtypes of HCC, and its usefulness for predicting the prognosis and treatment response of HCC patients was evaluated.
We distinguished three ARG clusters differing in terms of TME cell infiltration, immune cell activation status, clinicopathological features, and clinical outcomes. There were significant associations of ARG expression with tumor immunity, the epithelial-mesenchymal transition (EMT), and transforming growth factor-β expression. An ARG score model was constructed to generate a risk score for each patient based on differentially expressed genes between clusters. Furthermore, a high ARG score was associated with high expression of CTLA-4 and PD-L1/PD-1, and a low Tumor Immune Dysfunction and Exclusion score, indicating the usefulness of the ARG score for selecting patients for immunotherapy. Considering the relationship between ARGs and tumor immunity, immunotherapy combined with vascular-targeted therapy may be the best treatment for HCC.
ARGs play an important role in TME diversity and complexity in HCC patients. The ARG score of HCC predicts TME invasion and can guide immunotherapy.
肝细胞癌(HCC)是一种高度血管化的肿瘤,血管生成在其进展中起着重要作用。然而,血管生成在肿瘤微环境(TME)中细胞浸润中的作用尚不清楚。
我们评估了 35 个血管生成相关基因(ARGs)与 816 例 HCC 患者临床病理特征的相关性。此外,我们评估了 ARGs 与 TME 细胞浸润的相关性。构建了一个列线图来确定 ARGs 对 HCC 的预后价值。使用 ARG 评分区分 HCC 的血管生成亚型,并评估其预测 HCC 患者预后和治疗反应的能力。
我们根据 TME 细胞浸润、免疫细胞激活状态、临床病理特征和临床结局,区分了三个 ARG 簇。ARG 表达与肿瘤免疫、上皮-间充质转化(EMT)和转化生长因子-β表达显著相关。构建了一个 ARG 评分模型,根据簇间差异表达基因为每个患者生成风险评分。此外,高 ARG 评分与 CTLA-4 和 PD-L1/PD-1 的高表达以及低肿瘤免疫功能障碍和排除评分相关,表明 ARG 评分可用于选择免疫治疗患者。考虑到 ARGs 与肿瘤免疫之间的关系,免疫治疗联合血管靶向治疗可能是 HCC 的最佳治疗方法。
ARGs 在 HCC 患者的 TME 多样性和复杂性中起着重要作用。HCC 的 ARG 评分可预测 TME 浸润,并可指导免疫治疗。